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Abstract
Aims/hypothesis Dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, is indicated for improving glycaemic
control in type 2 diabetes mellitus. Whether its effects on HbA1c and other variables, including safety outcomes, in clinical trials
are obtained in real-world practice needs to be established.
Methods We used data from the comprehensive national diabetes register, the Scottish Care Information-Diabetes (SCI-
Diabetes) collaboration database, available from 2004 to mid-2016. Data within this database were linked to mortality data from
the General Registrar, available from the Information Services Division (ISD) of the National Health Service in Scotland. We
calculated crude within-person differences between pre- and post-drug-initiation values of HbA1c, BMI, body weight, systolic
blood pressure (SBP) and eGFR. We used mixed-effects regression models to adjust for within-person time trajectories in these
measures. For completeness, we evaluated safety outcomes, cardiovascular disease events, lower-limb amputation and diabetic
ketoacidosis, focusing on cumulative exposure effects, using Cox proportional hazard models, though power to detect such
effects was limited.
Results Among 8566 people exposed to dapagliflozin over a median of 210 days the crude within-person change in HbA1c was
−10.41 mmol/mol (−0.95%) after 3 months’ exposure. The crude change after 12 months was −12.99 mmol/mol (−1.19%) but
considering the expected rise over time in HbA1c gave a dapagliflozin-exposure-effect estimate of −15.14 mmol/mol (95% CI
−15.87, −14.41) (−1.39% [95% CI −1.45, −1.32]) at 12 months that was maintained thereafter. A drop in SBP of −4.32 mmHg
(95%CI −4.84, −3.79) on exposure within the first 3 months was also maintained thereafter. Reductions in BMI and body weight
stabilised by 6 months at −0.82 kg/m2 (95% CI −0.87, −0.77) and −2.20 kg (95% CI −2.34, −2.06) and were maintained
thereafter. eGFR declined initially by −1.81 ml min−1 [1.73 m]−2 (95% CI −2.10, −1.52) at 3 months but varied thereafter.
There were no significant effects of cumulative drug exposure on safety outcomes.
Conclusions/interpretation Dapagliflozin exposure was associated with reductions in HbA1c, SBP, body weight and BMI that
were at least as large as in clinical trials. Dapagliflozin also prevented the expected rise in HbA1c and SBP over the period of
study.
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SCI-Diabetes Scottish Care Information-Diabetes
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Introduction
Sodium–glucose cotransporter 2 (SGLT2) inhibitors block the
SGLT2within the proximal renal tubule, reducing glucose and
sodium reabsorption and increasing glycosuria and fluid loss.
Dapagliflozin is a new SGLT2 inhibitor indicated alongside
diet and exercise for improving glycaemic control in adults
with type 2 diabetes (licensed in Europe in 2012 [1] and the
USA in 2014 [2]). In randomised controlled trials (RCTs)
[3–10], dapagliflozin was found to improve glycaemic con-
trol, with mean difference in HbA1c of ~5.5 mmol/mol
(0.52%) vs control groups [11, 12]. Although not an indication
for use, RCTs of dapagliflozin have demonstrated weight loss
and improved systolic blood pressure (SBP) [3, 5, 6, 9, 10,
13]. In large-scale placebo-controlled cardiovascular disease
(CVD) outcome trials, other SGLT2 inhibitors (empagliflozin
[14] and canagliflozin [15]) were shown to reduce major CVD
events. Although the results for the dapagliflozin DECLARE
CVD outcome trial have not yet been published it has been
reported that the primary safety endpoint of non-inferiority for
major adverse cardiovascular events was met and that there
was a significant reduction in one of two primary efficacy
CVD endpoints [16, 17].
Over 3 years of real-world observational data are available
for dapagliflozin users in a large national electronic healthcare
record-derived dataset of individuals with type 2 diabetes in
Scotland, allowing effects on continuously distributed out-
comes HbA1c, BMI, body weight, SBP and kidney function
(as eGFR) to be evaluated. First, we aimed to determine
whether the effects of dapagliflozin on HbA1c and other var-
iables in RCTs are obtained in real-world practice. Second, we
aimed to undertake safety event outcome analyses, since safe-
ty concerns about SGLT2 inhibitors exist, to establish whether
an increased rate of these could be observed in dapagliflozin
users. Specifically, the Canagliflozin Cardiovascular
Assessment Study Programme demonstrated an unexpected
increased risk of lower-limb amputation (LLA) in patients
treated with canagliflozin [15] and the US Food and Drug
Administration (FDA)’s Adverse Reporting System showed
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a disproportionately increased reporting ratio for canagliflozin
and LLA. It is unclear whether increased LLA risk is a class
effect of SGLT2 inhibitors, is restricted to canagliflozin or is a
chance effect [18]. Case reports exist detailing the develop-
ment of (often euglycaemic) diabetic ketoacidosis (DKA) in
individuals with type 2 diabetes following initiation of SGLT2
inhibitor therapy, with increased disproportionality signalling
in both European Medicines Agency (EMA) and FDA
pharmacovigilance databases [19, 20]. It is unclear whether
this is a true drug effect.
It is important to understand the extent to which drug ef-
fects in RCTs are achieved in real clinical recipients who may
have a wider range of characteristics [21, 22]. Dapagliflozin is
licensed for those between 18 and 75 years of age, with an
eGFR ≥60mlmin−1 [1.73 m]−2 and not receiving pioglitazone
or loop diuretics. Some individuals not meeting these criteria
are nevertheless prescribed the drug.
We focus on dapagliflozin use in Scotland, as there are
sufficient dapagliflozin users to adequately power our analy-
ses (8566 dapagliflozin users, 1782 canagliflozin users and
2385 empagliflozin users in current data extract). As data ac-
crues, other SGLT2 inhibitors will be evaluated.
Methods
Data sources
Anonymised data were extracted from the Scottish Care
Information-Diabetes (SCI-Diabetes) collaboration database.
This database has been described in detail previously [23, 24]
and, in brief, comprises a nationwide register of e-health-
records containing extensive clinical data and issued prescrip-
tions for 99% of Scottish diabetes patients. These data are
linked using the Community Health Index, an identifier used
in all Scottish records, to mortality data from the General
Registrar and hospitalisation records available from the
Informatics Service Division of the National Health Service
in Scotland.
Study period and population
Data were available from 2004 until mid-2016 for all analyses.
Those eligible for inclusion into the study met the following
criteria: (1) alive with a diagnosis of type 2 diabetes at any
time since the introduction of dapagliflozin; (2) had no diag-
nosis of type 1 diabetes and (3) were aged 18–80 years upon
study entry. For the safety analyses, since we focus on cumu-
lative drug effect, a further criterion was imposed that persons
had to be fully evaluable for drug exposure since the date of
introduction of dapagliflozin or date of onset of diabetes,
whichever was later. For both analyses, individuals’ contrib-
uted person-time to the study upon the latest of study start
date, date of diagnosis of type 2 diabetes or becoming observ-
able within the dataset. Individuals ceased contributing
person-time to the study upon the earliest of death, becoming
unobservable within the dataset (i.e. lost due to emigration) or
study end date. For the safety analysis, individuals were cen-
sored following exposure to other SGLT2 inhibitors.
Informed consent
The study was carried out in accordance with the ethical prin-
ciples in the Declaration of Helsinki as revised in 2008.
Drug exposure
Issued prescription data were used to define drug expo-
sures. All prescriptions were assigned Anatomical
Therapeutic Chemical Classification System (ATC) codes;
dapagliflozin exposure was defined as ATC code
A10BX09/A10BK01. Dapagliflozin ever-users were those
with any initiation of dapagliflozin between November
2012 (the first date of dapagliflozin availability) and study
end date. Drug exposure start date was defined as the date
of initial prescription and drug exposure end dates were
extrapolated based on dosage, frequency and directions.
Dapagliflozin users were stratified to those receiving
dapagliflozin ‘on-licence’ (defined as age 18–75 years,
eGFR ≥60 ml min−1 [1.73 m]−2, not receiving pioglitazone
and not receiving loop diuretics) and ‘off-licence’ for indi-
viduals not fulfilling these criteria. Never-users were those
who never received a prescription for dapagliflozin
throughout the study period.
Clinical measures including outcome measures
The SCI-Diabetes database contains demographic data,
captures all HbA1c, serum creatinine and other biochemical
results, as well as all routine clinical measures such as
blood pressure, height and body weight. For baseline com-
parisons of demographic and clinical characteristics of
dapagliflozin users vs never-users, measurements for users
were taken as those closest to (but no earlier than
24 months before) dapagliflozin initiation. For never-users,
equivalent measurements were taken as those closest to
(but no earlier than 24 months before) the median initiation
date among users.
CVD, DKA and LLA were captured using linkage to na-
tional hospitalisation records and death data. ICD-10 codes
(http://apps.who.int/classifications/icd10/browse/2016/en) for
cause of admission and operative codes for amputations and
revascularisation surgeries were used to define events. CVD
codes included chronic ischaemic heart disease,
cerebrovascular disease, heart failure, cardiac arrhythmia or
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coronary revascularisation. See electronic supplementary
material (ESM) Table 1 for details.
Statistical methods
Simple descriptive statistics and linear or logistic regressions
adjusted for age, sex and diabetes duration were used to com-
pare characteristics of users and never-users. To evaluate the
effect of dapagliflozin on continuous clinical outcomes of in-
terest, we first described the distribution of within-person ab-
solute and percentage changes following dapagliflozin initia-
tion at regular intervals of 3 months throughout follow-up
among users. For this analysis, clinical outcomes were
assigned to time windows by applying a caliper of
±1.5 months (e.g. the 3 month time point contained measure-
ments observed between 1.5 and 4.5 months). For continuous
variable analyses, person-time was right-censored when
dapagliflozin was ceased, a diabetes drug that was co-
prescribed at dapagliflozin initiation was ceased or a new di-
abetes drug was started that was not already being received at
the dapagliflozin initiation date. Where another diabetes drug
was dropped at the time of initiation of dapagliflozin, the
record was included since that will be conservative with re-
spect to the apparent dapagliflozin effect. For analyses with
outcomes of SBP and for CVD events, person-time was also
right-censored upon initiating a new drug for CVD (all drugs
with first-level ATC code C) that was not received at
dapagliflozin initiation or ceasing a CVD drug that was co-
prescribed at dapagliflozin initiation.
Mixed-effects regression models of continuous outcomes
Simple analyses of pre/post-drug-initiation comparisons in
clinical outcomes in observational studies can provide mis-
leading estimates of apparent long-term efficacy if the under-
lying trend in that outcome in the absence of drug exposure is
not considered. Therefore, to assess the change in clinical
outcomes of interest following dapagliflozin exposure while
taking into consideration the underlying calendar time trend,
we constructed linear mixed-effects regression models (ESM
Methods) [25], which utilise pre-exposure data to control for
the expected within-person trajectories in the outcome of in-
terest in the absence of the drug. Clinical measurements up to
24 months before dapagliflozin initiation, and measurements
throughout the entire follow-up time until right-censoring,
were used.
To examine the likely magnitude of regression-to-the-mean
effects we constructed mixed regression models of the devia-
tion of within-person observed HbA1c from the expected
HbA1c at the time of drug initiation. For this analysis, we used
data from up to a maximum of 3 years prior to dapagliflozin
initiation. Fixed effects were specified as age, sex, duration of
diabetes, number of diabetes drug classes and month of
observation. Random effects and autocorrelation structure
were specified as for the primary analysis.
Cox regression models for event outcomes As we have de-
scribed in detail elsewhere, detecting drug effects on events is
subject to allocation bias if simple comparisons of event rates
in those ever vs never exposed are made [26]. Such bias is not
removed by adjustment for differences in observed risk factors
for the events between ever-users and never-users. We have
argued that for CVD, evaluation of cumulative effects on out-
comes is a more valid way to infer causality [26]. More spe-
cifically, Cox regression models for time-to-event were spec-
ified to include a time-updated term for ever-exposure vs
never-exposure (this term in fact captures the allocation bias)
and also to include a term for cumulative exposure. Person-
time was split into intervals of 28 days and each interval was
updated for exposure. Models were constructed with and
without adjustment for baseline clinical risk factors.
Imputation was used where risk factor data were missing
(see ESM Table 2). For events such as DKA, it might be
argued that if sudden rather than cumulative drug effects occur
then this effect would be captured in the ever vs never term but
it cannot be differentiated from allocation bias effects.
Results
Cohort descriptive statistics
In total, 8566 dapagliflozin users (of which 7231 were con-
sidered ‘on-licence’) and 230,310 never-users met inclusion
criteria for this analysis (Table 1 and ESM Table 3). In total,
2782 users (32.48%) had ceased dapagliflozin before their last
follow-up date and mean within-person persistence (i.e. pro-
portion of all available follow-up time in which dapagliflozin
continued to be received) was 0.81 (SD 0.32). During their
observable follow-up, 2576 users (30.07%) initiated at least
one additional diabetes drug they were not receiving at
dapagliflozin initiation (median time until additional diabetes
drug initiation was 214 days (interquartile range [IQR] 103–
381 days) and 1963 users (22.92%) ceased a non-
dapagliflozin diabetes drug that they had continued to receive
when dapagliflozin had been initiated (median time until ces-
sation of concurrent diabetes drug was 265 days [IQR 141–
453 days]). Thirty-two per cent of users discontinued another
diabetes drug at time of initiation of dapagliflozin and their
inclusion here is conservative with regard to estimating the
effect of dapagliflozin. Altogether, there were 6674 person-
years of follow-up time available post-initiation for evaluating
treatment effects and the median observation time post-
initiation (i.e. follow-up time was 210 days [IQR 91–
421 days]). Dapagliflozin was prescribed mostly as an add-
on therapy on top of existing monotherapy or dual therapy
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(Table 1). Baseline characteristics adjusted for age, sex and
diabetes duration differed considerably between users and
non-users (Table 1).
Crude within-person absolute changes in clinical
measures with dapagliflozin exposure
The mean (SD) number of measurements per user pre-
initiation were as follows: HbA1c 4.92 (1.99); BMI 3.58
(2.81); body weight 3.44 (2.81); SBP 5.44 (3.28) and eGFR
5.07 (3.62). The mean (SD) number of measurements per user
post-initiation were as follows: HbA1c 2.42 (1.71); BMI 2.13
(1.77); body weight 2.06 (1.70); SBP 2.68 (2.27) and eGFR
2.94 (3.12).
Crude within-person absolute changes in clinical outcomes
throughout follow-up are shown in Table 2 (with per cent
changes shown in ESM Table 4). Note that unlike in a clinical
trial where all measurements will occur at the same regularly
spaced intervals, our real-world observational dataset reflects
whatever clinical measures were made. Thus, different indi-
viduals contribute data within different 3 month windows be-
ing evaluated and there are of course fewer persons observed
at increasingly longer durations of follow-up. With these ca-
veats in mind, at 3 months the mean change in HbA1c was
−10.41 mmol/mol (−0.95%), with the largest change observed
Table 1 Baseline characteristics
of dapagliflozin users and never-
users
Characteristic All users Never users
n individuals 8566 230,310
Age, years 57.72 (9.96) * 66.13 (12.05)
Sex, % female 44.3 (43.2, 45.4) 43.5 (43.3, 43.7)
Duration of diabetes, years 11.36 (5.81) * 8.96 (6.80)
HbA1c, mmol/mol 77.71 (16.50) * 58.63 (17.34)
HbA1c, % 9.26 (1.51) * 7.51 (1.59)
BMI, kg/m2 34.27 (6.83) * 31.97 (6.31)
Body weight, kg 97.76 (21.72) * 90.84 (19.81)
SBP, mmHg 135.40 (15.54) * 132.98 (15.03)
DBP, mmHg 76.44 (9.46) * 75.06 (9.53)
eGFR, ml min−1 [1.73 m]−2 80.39 (16.29) * 77.99 (21.67)
Ever exposed to drugs for CVD, % 99.1 (99.0, 99.2) * 98.2 (98.1, 98.3)
Diabetes drug therapy pre-dapagliflozin initiation, %
No therapy 5.4 (4.9, 5.9) 27.0 (26.8, 27.2)
Insulin therapy 7.6 (7.1, 8.0) 7.1 (7.0, 7.2)
Monotherapy 32.0 (31.0, 33.0) 35.9 (35.7, 36.1)
Dual therapy 41.0 (39.9, 42.0) 22.4 (22.2, 22.6)
Triple therapy 11.2 (10.6, 11.8) 7.7 (7.6, 7.8)
≥ Four-class therapy 0.5 (0.4, 0.6) 0.5 (0.4, 0.5)
Clinical albuminuria status, %
Normoalbuminuria 75.2 (74.2, 76.2) 78.1 (77.9, 78.3)
Microalbuminuria 22.3 (21.3, 23.2) 18.8 (18.6, 19.0)
Macroalbuminuria 2.5 (2.2, 2.9) 2.8 (2.7, 2.9)
Smoking status, %
Current smoker 15.5 (14.8, 16.2) 18.3 (18.1, 18.5)
Ex-smoker 54.4 (53.4, 55.5) 51.8 (51.6, 52.0)
Never smoked 29.9 (28.9, 30.9) 29.3 (29.1, 29.5)
Prior morbidity, %
Heart failure 3.5 (3.1, 3.9) * 4.6 (4.5, 4.6)
Hypertension 29.4 (28.4, 30.5) 30.6 (30.4, 30.8)
Myocardial infarction 6.7 (6.1, 7.3) 7.2 (7.1, 7.3)
Stroke 2.3 (2.0, 2.7) * 3.6 (3.5, 3.6)
Transient ischaemic attack 1.2 (1.0, 1.5) 1.5 (1.5, 1.6)
Retinopathy status at last screening, %
No retinopathy 75.0 (74.1, 76.0) 79.5 (79.3, 79.7)
Mild retinopathy 19.3 (18.4, 20.2) 16.6 (16.5, 16.8)
Moderate retinopathy 1.0 (0.8, 1.2) 0.8 (0.7, 0.8)
Referable retinopathy 4.0 (3.6, 4.4) 2.7 (2.7, 2.8)
Data are shown as age-, sex- and diabetes-duration-adjusted mean (SD) for continuous variables and adjusted
proportions (95% CI) for categorical variables
* Significantly different (p < 0.05) for all users vs never users; using linear regression for continuous values
(adjusted for age sex and diabetes duration), logistic regression for binary values (adjusted for age sex and
duration) and χ2 for categorical values with ≤2 categories, after applying Bonferroni correction for multiple
testing
DBP, diastolic blood pressure
Diabetologia (2019) 62:621–632 625
Ta
bl
e
2
W
ith
in
-p
er
so
n
ch
an
ge
s
in
cl
in
ic
al
ou
tc
om
es
ov
er
tim
e
am
on
g
al
ld
ap
ag
lif
lo
zi
n
us
er
s
O
ut
co
m
e
B
as
el
in
e
3
m
on
th
s
6
m
on
th
s
9
m
on
th
s
12
m
on
th
s
15
m
on
th
s
18
m
on
th
s
21
m
on
th
s
24
m
on
th
s
27
m
on
th
s
30
m
on
th
s
To
ta
ln
o.
of
us
er
s
85
66
75
54
54
68
40
44
30
82
22
82
16
01
11
24
76
7
49
1
28
3
H
bA
1c
U
se
rs
w
ith
da
ta
,n
(%
)a
>
85
50
(>
96
)
39
80
(5
2.
7)
26
10
(4
7.
7)
16
80
(4
1.
5)
13
93
(4
5.
2)
85
9
(3
7.
6)
64
0
(4
0.
0)
41
9
(3
7.
3)
28
9
(3
7.
7)
16
5
(3
3.
6)
87
(3
0.
7)
A
bs
ol
ut
e
ch
an
ge
,m
m
ol
/m
ol
–
−1
0.
41
(1
4.
57
)
−1
1.
57
(1
6.
28
)
−1
1.
82
(1
5.
60
)
−1
2.
99
(1
5.
47
)
−1
1.
86
(1
5.
43
)
−1
1.
64
(1
6.
21
)
−1
0.
01
(1
5.
57
)
−1
0.
34
(1
6.
39
)
−9
.9
5
(1
4.
59
)
−1
0.
74
(1
7.
42
)
A
bs
ol
ut
e
ch
an
ge
,%
–
−0
.9
5
(1
.3
3)
−1
.0
6
(1
.4
9)
−1
.0
8
(1
.4
3)
−1
.1
9
(1
.4
2)
−1
.0
9
(1
.4
1)
−1
.0
6
(1
.4
8)
−0
.9
2
(1
.4
2)
−0
.9
5
(1
.5
0)
−0
.9
1
(1
.3
4)
−0
.9
8
(1
.5
9)
B
M
I
(k
g/
m
2
)
U
se
rs
w
ith
da
ta
,n
(%
)
77
87
(9
0.
9)
19
05
(2
5.
2)
14
15
(2
5.
9)
86
3
(2
1.
3)
73
7
(2
3.
9)
43
6
(1
9.
1)
29
6
(1
8.
5)
18
9
(1
6.
8)
14
9
(1
9.
4)
83
(1
6.
9)
47
(1
6.
6)
A
bs
ol
ut
e
ch
an
ge
–
−0
.7
4
(1
.1
4)
−0
.8
7
(1
.3
5)
−0
.9
0
(1
.2
9)
−0
.8
3
(1
.4
4)
−0
.9
3
(1
.4
8)
−0
.8
6
(1
.3
5)
−0
.9
8
(1
.5
2)
−0
.8
6
(1
.2
9)
−1
.0
4
(1
.4
4)
−0
.8
8
(1
.7
4)
B
od
y
w
ei
gh
t(
kg
)
U
se
rs
w
ith
da
ta
,n
(%
)
71
89
(8
3.
9)
15
89
(2
1.
0)
11
65
(2
1.
3)
72
6
(1
8.
0)
60
0
(1
9.
5)
35
2
(1
5.
4)
25
5
(1
5.
9)
16
3
(1
4.
5)
12
5
(1
6.
3)
64
(1
3.
0)
35
(1
2.
4)
A
bs
ol
ut
e
ch
an
ge
–
−2
.1
0
(3
.1
1)
−2
.3
7
(3
.7
0)
−2
.5
3
(3
.7
3)
−2
.3
8
(3
.5
5)
−2
.1
4
(4
.1
8)
−2
.6
2
(3
.7
8)
−2
.9
8
(4
.4
4)
−2
.7
5
(3
.9
0)
−3
.3
3
(4
.2
7)
−2
.5
3
(4
.7
4)
SB
P
(m
m
H
g)
U
se
rs
w
ith
da
ta
,n
(%
)
85
35
(9
9.
6)
28
11
(3
7.
2)
22
97
(4
2.
0)
15
38
(3
8.
0)
13
01
(4
2.
2)
83
6
(3
6.
6)
62
0
(3
8.
7)
39
1
(3
4.
8)
28
6
(3
7.
3)
15
1
(3
0.
8)
81
(2
8.
6)
A
bs
ol
ut
e
ch
an
ge
–
−4
.3
2
(1
6.
11
)
−4
.1
8
(1
5.
73
)
−3
.4
4
(1
6.
54
)
−2
.6
7
(1
6.
62
)
−3
.2
9
(1
6.
55
)
−4
.5
1
(1
7.
64
)
−5
.0
3
(1
6.
62
)
−5
.6
9
(1
7.
20
)
−4
.5
1
(1
9.
97
)
−6
.6
9
(1
7.
69
)
D
B
P
(m
m
H
g)
U
se
rs
w
ith
da
ta
,n
(%
)
85
35
(9
9.
6)
28
08
(3
7.
2)
22
97
(4
2.
0)
15
37
(3
8.
0)
13
01
(4
2.
2)
83
6
(3
6.
6)
62
0
(3
8.
7)
39
1
(3
4.
8)
28
6
(3
7.
3)
15
1
(3
0.
8)
81
(2
8.
6)
A
bs
ol
ut
e
ch
an
ge
–
−1
.8
9
(1
0.
12
)
−1
.8
7
(9
.9
8)
−1
.5
0
(1
0.
04
)
−1
.3
6
(9
.9
7)
−1
.8
5
(1
0.
23
)
−2
.6
7
(1
1.
49
)
−2
.3
1
(1
0.
40
)
−3
.5
6
(1
0.
96
)
−4
.1
4
(1
2.
30
)
−5
.5
4
(1
6.
48
)
eG
FR
(m
l
m
in
−1
[1
.7
3]
m
−2
)
U
se
rs
w
ith
da
ta
,n
(%
)
84
94
(9
9.
2)
33
05
(4
3.
8)
22
66
(4
1.
4)
15
72
(3
8.
9)
13
19
(4
2.
8)
82
5
(3
6.
2)
59
6
(3
7.
2)
40
6
(3
6.
1)
28
8
(3
7.
5)
16
4
(3
3.
4)
87
(3
0.
7)
A
bs
ol
ut
e
ch
an
ge
–
−1
.3
2
(9
.2
2)
−1
.3
8
(9
.5
3)
−1
.4
0
(9
.8
7)
−1
.4
8
(9
.6
7)
−1
.9
7
(1
0.
24
)
−1
.7
4
(9
.1
7)
−3
.4
9
(1
0.
03
)
−2
.3
0
(1
0.
68
)
−2
.9
8
(1
0.
17
)
−3
.1
4
(1
0.
92
)
U
se
rs
ar
e
sh
ow
n
as
n
(%
of
co
ho
rt
)
an
d
da
ta
fo
r
ab
so
lu
te
ch
an
ge
ar
e
sh
ow
n
as
m
ea
n
(S
D
)
di
ff
er
en
ce
in
th
e
ab
so
lu
te
w
ith
in
-p
er
so
n
av
er
ag
e
fr
om
th
e
ba
se
lin
e
va
lu
e
a
>
sy
m
bo
ls
ar
e
us
ed
w
he
re
di
ff
er
en
ce
s
ar
e
le
ss
th
an
10
an
d
st
at
is
tic
al
di
sc
lo
su
re
co
nt
ro
lh
as
be
en
ap
pl
ie
d
626 Diabetologia (2019) 62:621–632
at 12 months where it was −12.99 mmol/mol (−1.19%). The
change in HbA1c from baseline generally persisted above
−10 mmol/mol (−0.91%) throughout follow-up (Table 2). In
terms of target achievement by 6 months after initiation,
26.0% of users reached HbA1c ≤58 mmol/mol (7.5%) and
13.1% reached HbA1c ≤53 mmol/mol (7.0%) compared with
5.4% and 2.3% of users at baseline respectively. SBP, BMI
and body weight had all decreased by 3 months post-initiation
(crude within-person changes of −4.32 mmHg, −0.74 kg/
m2and −2.10 kg, respectively) and these changes persisted
thereafter.
Variability in effects by 24 months’ exposure
and effects of baseline characteristics
HbA1c was reduced in the majority of dapagliflozin recipients
but, as shown in a quadrant plot (ESM Fig. 1), the magnitude
of effect varied considerably. Using the most recently avail-
able treatment measure up to 24 months post-initiation, much
larger mean within-person absolute reductions were observed
for users in the highest two tertiles for baseline values of
HbA1c (ESM Table 5). Mean within-person HbA1c reductions
were also marginally more pronounced for users with a higher
baseline kidney function and shorter duration of diabetes. No
clear sex difference was observed. Similarly, those in the top
tertile for body weight, BMI and SBP had the highest absolute
decline in these outcomes. All observed subgroup effects
persisted when within-person changes were examined on a
proportional scale.
Crude effects by on-licence status
Mean within-person changes in the 84.4% of individuals con-
sidered to be on-licence users of dapagliflozin were similar to
the overall effect. Effects on HbA1c in the 15.6% of off-
licence-users were clearly observed and substantial but were
of slightly lower magnitude than those in the on-licence-users
(see ESM Tables 6, 7).
Effects from mixed-effects regression models
As shown in Table 2, crude absolute changes in clinical out-
comes compared with baseline were fairly stable over follow-
up time. Fitted mean trajectories of clinical outcomes from
final covariate-adjusted mixed regression models suggested
that before initiating dapagliflozin, HbA1c was increasing by
0.40% per year (Table 3), SBP was increasing by 0.59 mmHg
per year, BMI was decreasing by 0.03 kg/m2 per year, body
weight was decreasing by 0.12 kg per year and eGFR was
decreasing by 1.21 ml min−1 [1.73 m]−2 per year in these
users. However, there was substantial individual random var-
iation around these mean slopes.
In a mixed regression model taking account of time trends
in the clinical outcomes, the estimates for the apparent effect
of dapagliflozin on HbA1c at 3 months was similar to the
simple crude comparisons but the effect sizes yielded by the
model were greater than the crude estimates at longer follow-
up. Thus, the crude effect on HbA1c at 12 months was
−12.99 mmol/mol (−1.19%) whereas the estimate from the
model taking into consideration the upward change in
HbA1c that would have been expected in the absence of the
drug at that time point was −15.14 mmol/mol (95% CI
−15.87, −14.41) (−1.39% [95% CI −1.45, −1.32]), (Table 3
and Fig. 1a). Model effect estimates for BMI and body weight
showed stabilisation by 6 months, at a change of −0.82 kg/m2
(95% CI −0.87, −0.77) and −2.20 kg (95% CI −2.34, −2.06),
respectively (Table 3 and Fig. 1b, c). For SBP, dapagliflozin
was associated with a decrease of −4.32 mmHg (95% CI
−4.84, −3.79) within the first 3 months of use, that persisted
throughout follow-up (Table 3 and Fig. 1d). The pattern of
apparent effect of dapagliflozin upon kidney function was
less clear. An initial decline in eGFR of −1.81 ml min−1
[1.73 m]−2 (95% CI −2.10, −1.52) was observed within the
first 3 months of dapagliflozin use (Table 3 and Fig. 1e) but by
12 months the effect was no greater than the expected decline
in eGFR in the absence of drug. Estimates of treatment effects
were consistent whenmixed regressionmodel procedures were
restricted to data for on-licence-users only (data not shown).
Estimating potential magnitude of regression
to the mean on apparent drug-associated changes
Residual values from mixed regression models showed that
the closest prior measurements to dapagliflozin initiation ap-
peared systematically greater than expected given the respec-
tive individual HbA1c trajectories. This difference was ap-
proximately 10% on average but with considerable variability
in this estimate. Thus, for the change in HbA1c at 12months of
−15.14 mmol/mol (−1.39%), approximately 1.5 mmol/mol
(2.29%) might be attributable to this bias.
Safety event analysis
ESM Table 2 shows the results of fitting Cox proportional
hazards models for CVD, DKA and LLA. For this duration
of follow-up there were very few cases of CVD (n = 111) and
even fewer cases of DKA (n = 13) and LLA (n = 28) in the
exposed subgroup, such that power to detect effects was lim-
ited. Power was further limited for cumulative effects analysis
in that duration of exposure was short overall. Nonetheless we
show these data for completeness and have right-censored for
exposure to other SGLT2 inhibitors to ensure no negative
confounding effect balancing the non-significant effect ob-
served in the dapagliflozin-exposed group. As shown, there
was no significant effect of cumulative exposure on any of
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these outcomes. In the comparison of ever-users vs never-
users there was a significantly lower rate of CVD (HR 0.71,
p = 0.02), which was unchanged by adjustment for additional
clinical covariates for CVD events. While this is consistent
with a protective effect of the drug it is not proof of this since
this effect could also be due to allocation bias.
Discussion
We describe usage trends of dapagliflozin in individuals with
type 2 diabetes in Scotland. Almost all (84.4%) of those pre-
scribed dapagliflozin were on-licence users. Dapagliflozin
was largely prescribed as add-on therapy on top of one or
two drugs and was continued throughout follow-up for the
majority of people. As expected, dapagliflozin appeared to
be preferentially prescribed for younger individuals who had
poorer glycaemic control and longer duration of diabetes and
who were on more than one additional oral glucose-lowering
medication. Dapagliflozin use was associated with substantial
improvements in HbA1c and with slight improvements in
BMI, body weight and SBP. Based on follow-up values, the
greatest absolute improvements in glycaemic control were
observed for users with poorer baseline glycaemic control,
as well as users with shorter duration of diabetes and higher
kidney function. As well as an initial reduction in these out-
comes, dapagliflozin appeared to stabilise HbA1c and SBP so
that expected rises in these through time were prevented
across this median of 210 days of follow-up.
Real-world evidence can help corroborate findings from
RCTs by testing the generalisability of their reported treatment
effects and conclusions within a broader and more heteroge-
neous population who are less supervised in their healthcare
management. At 3–6 months, the crude and the modelled
estimated treatment effects onHbA1cwere slightly higher than
the effect sizes observed in previous RCTs. For example, at
3 months and 6 months, the observed crude mean reduction in
HbA1c from baseline was 10–12 mmol/mol (or −1.0 to −1.1%
units), compared with RCT estimates of −0.61% to −0.85% at
3 months and −0.5% to −1.4% at 6 months, subject to dosage
and additional drug therapies [3, 6, 27–31]. The US FDA
estimates the treatment effect of dapagliflozin on HbA1c to
Table 3 Estimated effects of time and dapagliflozin exposure from final covariate-adjusted linear mixed regression models predicting clinical
outcomes of interest
Variable HbA1c (mmol/mol) HbA1c (%) BMI (kg/m
2) Body weight (kg) SBP (mmHg) eGFR
(ml min−1
[1.73 m]−2)
Effect of time on
outcome, years
4.41
(4.15, 4.66)
0.40
(0.38, 0.43)
−0.03
(−0.05, 0.00)
−0.12
(−0.18, −0.06)
0.59
(0.36, 0.81)
−1.21
(−1.37, −1.06)
Change in outcome post-dapagliflozin initiation by time of follow-up
0–3 months −7.40
(−7.81, −7.00)
−0.68
(−0.71, −0.64)
−0.45
(−0.49, −0.41)
−1.35
(−1.46, −1.24)
−4.32
(−4.84, −3.79)
−1.81
(−2.10, −1.52)
3–6 months −11.64
(−12.12, −11.15)
−1.06
(−1.11, −1.02)
−0.82
(−0.87, −0.77)
−2.20
(−2.34, −2.06)
−4.27
(−4.87, −3.67)
−0.59
(−0.92, −0.26)
6–9 months −13.35
(−13.95, −12.75)
−1.22
(−1.28, −1.17)
−0.83
(−0.89, −0.78)
−2.25
(−2.42, −2.08)
−4.84
(−5.54, −4.13)
−0.56
(−0.96, −0.16)
9–12 months −15.14
(−15.87, −14.41)
−1.39
(−1.45, −1.32)
−0.85
(−0.92, −0.78)
−2.46
(−2.67, −2.25)
−3.72
(−4.59, −2.85)
−0.06
(−0.52, 0.40)
12–15 months −16.05
(−16.91, −15.19)
−1.47
(−1.55, −1.39)
−0.89
(−0.98, −0.81)
−2.31
(−2.56, −2.06)
−4.78
(−5.78, −3.78)
−0.24
(−0.77, 0.30)
15–18 months −16.61
(−17.64, −15.57)
−1.52
(−1.61, −1.43)
−0.93
(−1.04, −0.82)
−2.25
(−2.57, −1.93)
−4.12
(−5.41, −2.83)
0.37
(−0.28, 1.02)
18–21 months −16.87
(−18.15, −15.60)
−1.54
(−1.66, −1.43)
−0.89
(−1.02, −0.75)
−2.54
(−2.93, −2.16)
−6.48
(−8.06, −4.90)
−0.41
(−1.21, 0.39)
21–24 months −16.12
(−17.64, −14.60)
−1.47
(−1.61, −1.34)
−1.01
(−1.17, −0.84)
−2.71
(−3.18, −2.23)
−5.72
(−7.75, −3.69)
−1.19
(−2.12, −0.25)
>24 months −17.20
(−18.85, −15.55)
−1.57
(−1.72, −1.42)
−0.94
(−1.10, −0.78)
−2.32
(−2.80, −1.84)
−5.60
(−7.70, −3.50)
−0.65
(−1.63, 0.32)
Variation in random
intercepts, SD
5.01 0.46 0.50 1.32 5.88 4.61
Variation in random
slopes, SD
5.91 0.54 0.64 1.58 3.64 3.17
Data are shown as adjusted proportions (95% CI) for categorical variables
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be in the range −0.40% to −0.84%, which is smaller than our
findings [2, 32]. The National Institute for Health and Care
Excellence (NICE) in the UK estimates the same to be
−0.39% to −0.84%, which is also smaller than our findings
and similar to the US FDA estimate [33]. However, our esti-
mated effects of dapagliflozin upon HbA1c at 3–6 months
were consistent with reported follow-up values from a recent
UK-wide real-world retrospective study [34].
One potential reason for apparently higher treatment effects
in an observational study is regression to the mean. Where
there is considerable short-term within-person variation (or
‘noise’) in clinical measures, whether due to true short-term
biological variability or to measurement error, a new drug is
more likely to be prescribed in response to extreme or outlying
clinical observations such as unusually high HbA1c for the
respective individual. Even where a drug is ineffective post-
vs pre-initiation, comparisons of data might show an apparent
treatment effect, as after a given extreme observation
subsequent measurements might be expected to regress to
the mean. It is also the case that true biological worsening of
the clinical measure such as HbA1c will also precede new drug
intervention. The combined effect of these two phenomena is
that HbA1c at the time of drug initiation is likely to be system-
atically higher than expected given an individual’s prior mea-
surements, their current characteristics of age, sex, diabetes
duration and other characteristics relevant to expected
HbA1c. Precisely how much of the observed treatment effect
is attributable to regression-to-the-mean effects is not directly
estimable. By examining the residuals of the last measure-
ments prior to dapagliflozin initiation in a model of pre-
initiation trajectories, we have provided a crude estimate of
the magnitude of such effects as being an apparent reduction
of about 10% of the apparent treatment effect. The treatment
effects we observed on HbA1c at 3–6 months were 0.15–
0.30% units higher than in clinical trials but half of this dif-
ference might be explained by regression to the mean. The
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apparently greater effects could also be because any changes
in lifestyle that reduce HbA1c could co-occur upon drug
initiation.
Our observed treatment effects at 3–6 months upon BMI,
body weight and SBP were highly consistent with those from
RCTs wherein reported effects on body weight were −1.50 kg
to −3.2 kg and effects on SBPwere −2.19 to −3.9 mmHg [3, 5,
6, 27–29, 31]. The effects on SBP are consistent with the
mechanisms of action of the drug, which encourages renal
sodium and glucose loss.
An important aspect of our analyses is the persistence of the
apparent drug effect. Since HbA1c and SBP tend to worsen
over time in diabetes in the absence of drug exposure, a stable
absolute difference from baseline over longer follow-up is
consistent not only with the drug not only improving the
HbA1c and SBP but also preventing their worsening over time.
This is illustrated in the mixed model where a much larger net
effect of dapagliflozin on HbA1c of −16 mmol/mol (−1.47%)
given its underlying time trend was estimated at 24 months of
exposure.
The vast majority of people receiving dapagliflozin re-
spond to the drug but there is considerable variation in the
magnitude of the response. We are not able to evaluate in this
study to what extent such variation reflects true biological
variation in response vs differences in compliance. Some of
the variation on an absolute scale reflects that the largest re-
ductions in HbA1c during follow-up were seen for those users
in the highest tertile for baseline HbA1c (ESM Table 5).
Individuals also generally exhibited wide variation in re-
sponses in clinical trials (SD for HbA1c effect ranging from
0.61% to 0.92%), though the wider variation seen here may
reflect the broader diversity of individuals’ characteristics in
our real-world dataset as well as more diverse compliance
[3–7, 10].
Currently, the most common reported adverse effect report-
ed in RCTs of dapagliflozin is a higher risk of urinary and
genital tract infections [9, 10, 35]. There is also some evidence
that dapagliflozin is associated with a risk of decline in kidney
function, though this association did not persist in subgroups
with long-term treatment (>24 months), consistent with our
observation of an initial decline in eGFR, which by 12months
was consistent with the annual decline expected in the absence
of drug (Fig. 1e) [36]. Dapagliflozin treatment is not currently
recommended for individuals with an eGFR below
60 ml min−1 [1.73 m]−2 [1, 14, 15]. Our focus here was on
effects on continuous outcomes for which there is adequate
power rather than on CVD and other safety-events analyses
for which power is very low. Nonetheless, we included such
analyses for completeness. No significant safety signals were
found. While there was a significantly lower CVD event rate
in those ever vs never exposed, there was no significant cu-
mulative effect of exposure on CVD. As we have described
previously, such ever vs never comparisons, while providing
some reassurance, cannot be interpreted as proof of a protec-
tive causal effect since they remains subject to allocation bias.
As further follow-up data accrues in this dataset, we will be
able to test for cumulative effects on events with more power.
In addition, we intend to explore effects of other SGLT2 in-
hibitors that were licensed later as further data accrue.
We acknowledge the limitations of our analysis, the most
important of which is that unbiased control comparisons can-
not be achieved as they are in clinical trials. In addition, as
described, within-person analyses can fail to take into account
regression to the mean and underlying calendar time trends.
Nevertheless, we have made extensive efforts to estimate the
likely magnitude of these latter two biases, going well beyond
many observational studies of this nature.
In conclusion, the effectiveness of dapagliflozin on
HbA1c and other clinical outcomes observed in clinical
trials was apparent in this real-world effectiveness study;
treatment effect estimates were at least as large as in
clinical trials even when likely observational analysis
biases are considered. Dapagliflozin lowers HbA1c and
SBP shortly after treatment initiation but also appears
to prevent worsening of these outcomes over the ensuing
2 years. Dapagliflozin also lowered BMI and body
weight.
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